Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.
about
The European Hematology Association Roadmap for European Hematology Research: a consensus documentMeasurable residual disease testing in acute myeloid leukaemia.Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.Molecular response in CML: where is the bar?Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.Milestones and monitoring.Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitorsAnalysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma.The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.A review of the European LeukemiaNet recommendations for the management of CML.Update on emerging treatments for chronic myeloid leukemia.Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.The Role of Early Molecular Response in the Management of Chronic Phase CML.Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.Imatinib for the treatment of hypereosinophilic syndromes.Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia.Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia.Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.Critical methodological factors in diagnosing minimal residual disease in hematological malignancies using quantitative PCR.[Chronic myelogenous leukemia].Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UKQuantitative prediction of long-term molecular response in TKI-treated CML - Lessons from an imatinib versus dasatinib comparisonBCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors
P2860
Q28830861-DF617950-E918-4214-895F-311932296724Q30234914-DA9B3C73-DA1B-462C-A3F0-358C47A5EAE2Q30891587-C7E22330-577C-450D-8A35-8A6786D41B4DQ33948671-9F66CE3D-A1AC-4C66-88B3-8BB14783F808Q34155213-610A10C4-D1F9-48FC-AE5E-9605F148C84AQ35652844-91B964DA-27E4-44B9-89E8-7A2CD2C83A1CQ36263943-69475F93-B6A8-4D26-ABA3-264CC8834BB1Q36442499-7D914893-0115-453B-83E3-1EC325FA1C20Q36675052-6FF5E9FC-5A87-4689-8762-D9B9815C07CDQ36734508-3A478151-8396-4E37-9534-4DFCBB6840FBQ37327618-F41F23D0-482D-4F24-BB79-5A6EB6F29180Q37714627-8C2BA063-437D-458D-94C6-7D6B13B7D373Q38392676-61DD4339-78CC-4C27-BF8F-CEC78F3F60D0Q38397515-748B1B50-A7A7-4D4C-899D-525FA1C52A92Q38562354-305C6EE1-24D1-4AEB-8FFD-A50B43AA1A8EQ38685803-99604F66-20FA-4928-86FB-5153980E0F75Q38725366-493B94B5-49DE-49DA-B74D-0CD191FAFF35Q38797683-4B845FBF-7CF4-41F7-94B7-B38265A93E78Q39239805-180AEB42-B99D-4ED8-A362-691B282740E6Q40821920-4F3E5292-72F4-4D51-B33C-E94A80676D40Q41661752-7FCE40FF-48D3-41EE-841F-554746433167Q46007169-A24A54FD-FC17-4E48-934A-C86CE4BE4F7AQ49101349-2E6156F6-967E-42F3-AB20-7140DFC4E587Q50177622-477E2630-85FE-49BF-BA06-FBBF1A8CD078Q50279978-58C9DDD9-B8FB-487B-8CF9-B92A1DF34505Q50997822-963FF8CC-D1D5-45F2-BDA1-BF00A33886B3Q52567954-B9714BA6-80A0-41B7-8CC1-AD8508255E05Q52886333-31C6FC52-06D5-4548-9B6F-5D4CB5C1B84DQ53215863-C5037F22-A355-4C97-A20D-633119F753DFQ53610644-A5D81D8E-A6C0-4AD5-9D1E-AA517358880AQ54167458-52C6E539-7549-4FE8-98C7-8814C0931403Q58455606-7B9CCE5A-D054-4AAD-ACD0-7938DC226753Q58771228-EDBCCC14-BE0E-4992-975C-51F14594A5D1Q58778554-6360C419-0551-4170-A243-166F6EE728B7
P2860
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Velocity of early BCR-ABL tran ...... se on treatment with imatinib.
@en
Velocity of early BCR-ABL tran ...... me in chronic myeloid leukemia
@nl
type
label
Velocity of early BCR-ABL tran ...... se on treatment with imatinib.
@en
Velocity of early BCR-ABL tran ...... me in chronic myeloid leukemia
@nl
prefLabel
Velocity of early BCR-ABL tran ...... se on treatment with imatinib.
@en
Velocity of early BCR-ABL tran ...... me in chronic myeloid leukemia
@nl
P2093
P2860
P50
P356
P1433
P1476
Velocity of early BCR-ABL tran ...... ase on treatment with imatinib
@en
P2093
A Fabarius
A Neubauer
B Hanfstein
C F Waller
F Stegelmann
G M Baerlocher
P2860
P2888
P304
P356
10.1038/LEU.2014.153
P577
2014-05-06T00:00:00Z